Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea

Trial Profile

Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Alcaftadine (Primary)
  • Indications Allergic conjunctivitis
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 09 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top